This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pletz, M. W. R. Articles by Lode, H. Search for Related Content PubMed PubMed Citation Articles by Pletz, M. W. R. Articles by Lode, H.

Early Bactericidal Activity of Moxifloxacin in Treatment of Pulmonary Tuberculosis: a Prospective, Randomized Study

Department of Chest and Infectious Diseases, City Hospital Emil von Behring/Chest Hospital Heckeshorn,¹ Institute of Microbiology, City Hospital Emil von Behring, Freie Universität Berlin, 14195 Berlin, Germany²

Received 18 August 2003/ Returned for modification 14 October 2003/ Accepted 11 November 2003

Moxifloxacin is the most active fluoroquinolone against Mycobacterium tuberculosis in vitro. However, data about the efficacy in patients are not available. We enrolled 17 patients with tuberculosis in a prospective, randomized study. After 5 days of monotherapy with either moxifloxacin or isoniazid, we detected significant decreases in mean CFU per milliliter in sputum in both groups. The calculated early bactericidal activities for isoniazid and moxifloxacin were 0.209 and 0.273 log₁₀ CFU per ml of sputum per day, respectively. According to the data from our study, moxifloxacin exhibits an early bactericidal activity that is comparable to that of isoniazid.

This article has been cited by other articles:

• Burman, W. J., Goldberg, S., Johnson, J. L., Muzanye, G., Engle, M., Mosher, A. W., Choudhri, S., Daley, C. L., Munsiff, S. S., Zhao, Z., Vernon, A., Chaisson, R. E., and the Tuberculosis Trials Consortium, (2006). Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis. Am. J. Respir. Crit. Care Med. 174: 331-338 [Abstract] [Full Text]  
• Gillespie, S. H., Gosling, R. D., Uiso, L., Sam, N. E., Kanduma, E. G., McHugh, T. D. (2005). Early bactericidal activity of a moxifloxacin and isoniazid combination in smear-positive pulmonary tuberculosis. J Antimicrob Chemother 56: 1169-1171 [Abstract] [Full Text]  
• Weber, J. T. (2005). Appropriate Use of Antimicrobial Drugs: A Better Prescription Is Needed. JAMA 294: 2354-2356 [Full Text]  
• Marra, F., Marra, C. A., Moadebi, S., Shi, P., Elwood, R. K., Stark, G., FitzGerald, J. M. (2005). Levofloxacin Treatment of Active Tuberculosis and the Risk of Adverse Events. Chest 128: 1406-1413 [Abstract] [Full Text]  
• Gumbo, T., Louie, A., Deziel, M. R., Drusano, G. L. (2005). Pharmacodynamic Evidence that Ciprofloxacin Failure against Tuberculosis Is Not Due to Poor Microbial Kill but to Rapid Emergence of Resistance. Antimicrob. Agents Chemother. 49: 3178-3181 [Abstract] [Full Text]  
• Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., Williams, K., Rosenthal, I., O'Brien, R. J., Vernon, A. A., Chaisson, R. E., Bishai, W. R., Grosset, J. H. (2004). Moxifloxacin-containing Regimens of Reduced Duration Produce a Stable Cure in Murine Tuberculosis. Am. J. Respir. Crit. Care Med. 170: 1131-1134 [Abstract] [Full Text]  
• Gosling, R., Gillespie, S., Pletz, M. W. R., Lode, H. (2004). Moxifloxacin Treatment of Tuberculosis. Antimicrob. Agents Chemother. 48: 3642-3643 [Full Text]